Ansaldi Filippo, Bacilieri Sabrina, Durando Paolo, Sticchi Laura, Valle Laura, Montomoli Emanuele, Icardi Giancarlo, Gasparini Roberto, Crovari Pietro
CIRI-IV, Department of Health Sciences, University of Genoa, Genoa, Italy.
Vaccine. 2008 Mar 17;26(12):1525-9. doi: 10.1016/j.vaccine.2008.01.019. Epub 2008 Feb 1.
Adjuvants enhance antibody response against vaccination. We compared the ability of MF59-adjuvanted and non-adjuvanted subunit influenza vaccines, containing A/Wyoming/3/03(H3N2), to confer cross-protection against four consecutive drifted strains in the elderly. Neutralizing and haemagglutination-inhibiting antibody were measured. MF59-adjuvanted vaccine induced a stronger booster response against A/Panama/2007/99(H3N2) than non-adjuvanted vaccine. A/Panama/2007/99(H3N2) circulated widely during the previous 5 years and was included in vaccines over four consecutive seasons. Broader serological protection against drifted strains that circulated 1 and 2 years after vaccination with A/Wyoming/3/03(H3N2) was observed with MF59-adjuvanted vaccine. Thus, MF59-adjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations.
佐剂可增强疫苗接种后的抗体反应。我们比较了含A/怀俄明/3/03(H3N2)的MF59佐剂亚单位流感疫苗和非佐剂亚单位流感疫苗在老年人中针对四种连续变异毒株提供交叉保护的能力。检测了中和抗体和血凝抑制抗体。与非佐剂疫苗相比，MF59佐剂疫苗对A/巴拿马/2007/99(H3N2)诱导出更强的加强反应。A/巴拿马/2007/99(H3N2)在过去5年中广泛传播，并连续四个季节被纳入疫苗。使用MF59佐剂疫苗接种A/怀俄明/3/03(H3N2)后1年和2年，观察到对变异毒株有更广泛的血清学保护。因此，在易感人群中，MF59佐剂疫苗比非佐剂疫苗具有更高的免疫原性。
